New drug LAD191 tested for safety in autoimmune patients
NCT ID NCT06488209
First seen Nov 25, 2025 · Last updated Jun 18, 2026 · Updated 25 times
Summary
This early-phase study tested the safety and tolerability of a new drug called LAD191 in 69 healthy adults and people with an autoimmune disease. Researchers gave single or multiple doses to see how the body processes the drug and if it causes side effects. The goal was to gather initial safety data, not to treat the disease. This is a first step before larger studies can explore whether LAD191 might help control autoimmune conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Doral Medical Research
Miami, Florida, 33165, United States
-
ICON Early Phase Services, LLC
San Antonio, Texas, 78209, United States
-
Jennifer Parish, MD
Philadelphia, Pennsylvania, 19103, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.